莱伯泰科(688056) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 was CNY 402.23 million, a decrease of 5.14% compared to the previous year[3] - Operating profit increased by 4.26% to CNY 45.61 million, while total profit rose by 3.83% to CNY 45.41 million[5] - Net profit attributable to shareholders of the parent company was CNY 39.38 million, reflecting a slight increase of 0.59% year-on-year[5] - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 33.06 million, up 6.77% from the previous year[5] - Total assets at the end of the reporting period were CNY 933.02 million, a decrease of 2.37% from the beginning of the year[5] - Shareholders' equity attributable to the parent company was CNY 809.25 million, down 1.02% from the start of the year[5] Operational Strategy - The company maintained stable gross profit margins across all product lines, with absolute amounts of various period expenses decreasing[5] - The company is transitioning from a laboratory instrument manufacturer to a full-process partner for laboratories, focusing on comprehensive solutions[6] - The company is enhancing its R&D efforts in new materials, new energy, and new pollutants to maintain competitive advantages[6] - The company is actively pursuing business development through talent acquisition, team building, and new product development[6]